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Juvenile arthritis disease activity score is a
better reﬂector of active disease than the
disease activity score 28 in adults with
polyarticular juvenile idiopathic arthritis
A considerable proportion of children with polyarticular juven-ile 
idiopathic arthritis (polyJIA) experience active disease into 
adulthood.1 However, there is no validated disease activity 
measure for adults with polyJIA, and they are often assessed using 
the disease activity score 28 (DAS28). DAS28 is validated in 
adults with rheumatoid arthritis (RA), and determines qualiﬁ-
cation for biological drugs in the UK and other countries.2 3  In 
contrast to the juvenile arthritis disease activity score ( JADAS),4 
DAS28 does not fully evaluate the pattern of joint involvement 
often observed in polyJIA. In this study, we compared DAS28 
with JADAS-10 in adolescents and adults with polyJIA.
Tender and swollen joint counts out of 28, active joint count of 
all joints up to a maximum of 10, patient/parent and physician 
global assessment visual analogue scales were collected from 
clinics in patients aged ≥10 years with polyJIA (International 
League of Associations for Rheumatology classiﬁcation criteria 
for rheumatoid factor-negative (RhF-ve) or rheumatoid factor-
positive (RhF+ve) polyJIA). Erythrocyte sedimentation rate 
(ESR) values were taken within 30 days before or after 
assessment. When unavailable, values were taken within 3 months 
before or after, provided the patient remained stable between the 
ESR test and assessment. When unavailable within these time 
periods, patients were excluded from analysis. DAS28 and 
JADAS-10 were calcu-lated and compared using Spearman’s rank 
correlation coefﬁcient. DAS28>5.1 constitutes high-disease 
activity in adults with RA, ≤3.2 suggests low-disease activity or 
remission.2 3 In children with polyJIA, JADAS-10>10.5 is 
considered to reﬂect high-disease activity,5 ≤3.8 reﬂects low or 
inactive disease.6 7
Forty-nine patients (36 polyJIA-RhF-ve, 10 polyJIA-RhF+ve, 3 
unknown RhF) were analysed (range=10–27 years, median=15 
years, M:F ratio 1:3.5). Good correlation was seen between the 
disease activity scores (Spearman’s r=0.69, p<0.0001). 
However, when looking at values above cut-offs deﬁned for active 
disease, considerable underestimation of disease activity by 
DAS28 was observed with 13 patients having JADAS-10>10.5 
but only 1 of these patients having DAS28>5.1 (ﬁgure 1).
There was no considerable difference in correlation between 
disease activity scores between adolescents (range=10–15 years, 
median=13 years, n=25, Spearman’s r=0.83, p<0.0001) and 
adults (range=16–27 years, median=17 years, n=24, 
Spearman’s r=0.73, p<0.0001), nor between polyJIA-RF-ve
(n=36, Spearman’s r=0.68, p<0.0001) and polyJIA-RF+ve
(n=10, Spearman’s r=0.80, p=0.0088).
Although previous studies found good correlations between
DAS28 and JADAS in children with JIA,8 this is the ﬁrst to
include the adult population and highlight a discrepancy in
thresholds for high-disease activity between DAS28 and JADAS.
Looking at individual patients, 9 out of 10 patients with
active disease deﬁned by JADAS (table 1) had joints deemed to
be active that are not included in the DAS28 joint count, thus
contributing to a high JADAS but not affecting DAS28. It would
be pertinent to also calculate DAS44, but data were incomplete.
If total active joints are greater than DAS28 swollen or tender
joints, this could strongly imply JADAS incorporates joints
outside those surveyed by DAS28. Seventy-ﬁve per cent of
patients with active disease deﬁned by JADAS but not DAS28
had higher total active joints than 28 tender or swollen joints
compared with 17% of those patients not classiﬁed as active by
JADAS and DAS28. This further suggests that a discrepancy in
the proportion of patients with active disease as deﬁned by
JADAS and DAS28 respectively is predominantly due to differ-
ences in the number and distribution of joints surveyed.
In many countries where DAS28 is used in adults with polyar-
thritis regardless of age of onset, this may have important impli-
cations when determining which patients qualify for biological
drugs. These data support ongoing use of JADAS as the more
appropriate disease activity measure to use in adults with
polyJIA. A larger study to determine how this may impact on
therapeutic decisions is warranted.
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Figure 1 Scatter plot with linear regression line of juvenile arthritis
disease activity score 10 ( JADAS-10, x-axis) and disease activity score
28 (DAS28, y-axis). Despite good correlation between these disease
activity measures, there is a discrepancy in the threshold for
high-disease activity between JADAS-10 ( JADAS-10 >10.5, vertical
dotted line) and DAS28 (DAS28 >5.1, horizontal dotted line). Also, 13
out of 49 patients were classiﬁed as high-disease activity by JADAS-10
(data points to the right of the vertical dotted line), and of these, only
1 was deﬁned as also being high-disease activity by DAS28 (data point
above the horizontal dotted line). No patients were classiﬁed as high
activity for DAS28 but not high according to JADAS-10.
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Table 1 Joint counts in patients with active disease as defined by juvenile arthritis disease activity score-10
Patient
code Tender joints Swollen joints Active joints
RF
status
13 L ankle None L ankle, L subtalar Neg
17 R knee R knee R knee, L ankle, R ankle, L subtalar,
R subtalar, L midfoot, R midfoot
Neg
30 L TMJ, R TMJ L index MCP, R index MCP,
L middle MCP, R middle MCP
L TMJ, R TMJ, 2 MCPs Pos
31 Unknown Unknown Unknown Neg
33 L wrist, R wrist, R middle MCP,
L knee, R knee, L ankle, R ankle
L wrist, R wrist, R middle MCP,
L knee, R knee, L ankle, R ankle
L wrist, R wrist, R middle MCP, L knee, R knee, L ankle, R ankle Pos
36 6 MCPs, L ankle, L subtalar L elbow, L wrist, R wrist, 6 MCPs,
6 PIPs, L ankle, R ankle,
L subtalar, R subtalar
L elbow, R wrist, 7 MCPs, L ankle, L subtalar Neg
38 L TMJ, R TMJ, L shoulder, L elbow,
5 MCPs, thumb CMC
L elbow, thumb CMC, L knee L TMJ, R TMJ, L shoulder, L elbow, 10 MCPs,
L thumb CMC, R thumb CMC, L knee
Neg
41 Unknown Unknown Unknown Pos
44 L shoulder, R shoulder, L wrist,
R wrist, L ring MCP, R ring MCP,
L little MCP, R little MCP
L ring MCP, R ring MCP,
L little MCP, R little MCP
L shoulder, R shoulder, L wrist, R wrist,
L ring MCP, R ring MCP, L little MCP, R little MCP, R hip
Neg
49 None Unknown Unknown Neg
50 R wrist, L knee, L ankle None R wrist, L knee, L ankle Neg
56 L TMJ, R TMJ, 2 finger joints 4 finger joints L TMJ, R TMJ, 4 finger joints Neg
58 L wrist, R wrist, 9 MCPs, 8 PIPs L wrist, 10 MCPs, 10 PIPs L wrist, R wrist, 10 MCPs, 10 PIPs Pos
Joints not included within the DAS28 joint count are shown in bold.
CMC, carpometacarpal joint; L, left; MCP, metacarpophalangeal joint; Neg, negative; PIP, proximal interphalangeal joint; Pos, positive; R, right; RF, rheumatoid factor; TMJ,
temporomandibular joint.
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